|Articles|March 1, 2003

Coughing up a throat culture

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

ByCharles Vega, MD, FAAFP

September 10th 2026

Navepegritide shows early safety and growth signals in infants with achondroplasia | Image Credit: © Gorodenkoff - stock.adobe.com.

Navepegritide shows early safety and growth signals in infants with achondroplasia

ByMorgan Ebert, Executive Editor

September 10th 2026

A teenaged girl with flat-topped papules

A teenaged girl with flat-topped papules

ByZeena Mestari,Bernard A Cohen, MD

September 9th 2026

Vosoritide improves growth velocity in children with hypochondroplasia, phase 3 trial shows | Image Credit: © HockleyM2/peopleimages.com - stock.adobe.com.

Vosoritide improves growth velocity in children with hypochondroplasia, phase 3 trial shows

ByMorgan Ebert, Executive Editor

September 9th 2026

CDC-backed surveillance finds 4 in 5 child deaths preventable across 7 high-mortality countries | Image Credit: © JHVEPhoto - stock.adobe.com.

CDC-backed surveillance finds 4 in 5 child deaths preventable across 7 high-mortality countries

ByMorgan Ebert, Executive Editor

September 9th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

CDC-backed surveillance finds 4 in 5 child deaths preventable across 7 high-mortality countries

A teenaged girl with flat-topped papules

Bifidobacteria Decline: Causes and Consequences for Infant Gut Health

Semaglutide improves BMI category in children aged 6 to 11 years in phase 3 trial

Vosoritide improves growth velocity in children with hypochondroplasia, phase 3 trial shows